期刊文献+
共找到4篇文章
< 1 >
每页显示 20 50 100
Inherited arrhythmias and gene therapy: Are there any ethical considerations to take into account? 被引量:1
1
作者 Michael Spartalis Eleftherios Spartalis gerasimos siasos 《World Journal of Cardiology》 2023年第12期623-626,共4页
Interventional electrophysiology represents a relatively recent subspecialty within the field of cardiology.In the past half-century,there has been significant advan-cement in the development and implementation of inn... Interventional electrophysiology represents a relatively recent subspecialty within the field of cardiology.In the past half-century,there has been significant advan-cement in the development and implementation of innovative ablation treatments and approaches.However,the treatment of arrhythmias continues to be inade-quate.Several arrhythmias,such as ventricular tachycardia and atrial fibrillation,pose significant challenges in terms of therapeutic efficacy,whether through interventional procedures or the administration of antiarrhythmic drugs.Cardio-logists are engaged in ongoing research to explore innovative methodologies,such as genome editing,with the purpose of effectively managing arrhythmias and meeting the growing needs of patients afflicted with rhythm disturbances.The field of genome editing has significant promise and has the potential to serve as a highly effective personalized therapy for rhythm disorders in patients.However,several ethical issues must be considered. 展开更多
关键词 ARRHYTHMIA Sudden cardiac death Genome editing Long QT Channelo-pathies Mutation
下载PDF
Efficient differentiation of vascular smooth muscle cells from Wharton's Jelly mesenchymal stromal cells using human platelet lysate: A potential cell source for small blood vessel engineering 被引量:2
2
作者 Panagiotis Mallis Aggeliki Papapanagiotou +5 位作者 Michalis Katsimpoulas Alkiviadis Kostakis gerasimos siasos Eva Kassi Catherine Stavropoulos-Giokas Efstathios Michalopoulos 《World Journal of Stem Cells》 SCIE CAS 2020年第3期203-221,共19页
BACKGROUND The development of fully functional small diameter vascular grafts requires both a properly defined vessel conduit and tissue-specific cellular populations.Mesenchymal stromal cells(MSCs) derived from the W... BACKGROUND The development of fully functional small diameter vascular grafts requires both a properly defined vessel conduit and tissue-specific cellular populations.Mesenchymal stromal cells(MSCs) derived from the Wharton's Jelly(WJ) tissue can be used as a source for obtaining vascular smooth muscle cells(VSMCs),while the human umbilical arteries(h UAs) can serve as a scaffold for blood vessel engineering.AIM To develop VSMCs from WJ-MSCs utilizing umbilical cord blood platelet lysate.METHODS WJ-MSCs were isolated and expanded until passage(P) 4. WJ-MSCs were properly defined according to the criteria of the International Society for Cell and Gene Therapy. Then, these cells were differentiated into VSMCs with the use of platelet lysate from umbilical cord blood in combination with ascorbic acid,followed by evaluation at the gene and protein levels. Specifically, gene expression profile analysis of VSMCs for ACTA2, MYH11, TGLN, MYOCD, SOX9,NANOG homeobox, OCT4 and GAPDH, was performed. In addition,immunofluorescence against ACTA2 and MYH11 in combination with DAPI staining was also performed in VSMCs. HUAs were decellularized and served as scaffolds for possible repopulation by VSMCs. Histological and biochemical analyses were performed in repopulated h UAs.RESULTS WJ-MSCs exhibited fibroblastic morphology, successfully differentiating into"osteocytes", "adipocytes" and "chondrocytes", and were characterized by positive expression(> 90%) of CD90, CD73 and CD105. In addition, WJ-MSCs were successfully differentiated into VSMCs with the proposed differentiation protocol. VSMCs successfully expressed ACTA2, MYH11, MYOCD, TGLN and SOX9. Immunofluorescence results indicated the expression of ACTA2 and MYH11 in VSMCs. In order to determine the functionality of VSMCs, h UAs were isolated and decellularized. Based on histological analysis, decellularized h UAs were free of any cellular or nuclear materials, while their extracellular matrix retained intact. Then, repopulation of decellularized h UAs with VSMCs was performed for 3 wk. Decellularized h UAs were repopulated efficiently by the VSMCs. Biochemical analysis revealed the increase of total hydroyproline and s GAG contents in repopulated h UAs with VSMCs. Specifically, total hydroxyproline and s GAG content after the 1 st, 2 nd and 3 rd wk was 71 ± 10, 74 ± 9 and 86 ± 8 μg hydroxyproline/mg of dry tissue weight and 2 ± 1, 3 ± 1 and 3 ± 1μg s GAG/mg of dry tissue weight, respectively. Statistically significant differences were observed between all study groups(P<0.05).CONCLUSION VSMCs were successfully obtained from WJ-MSCs with the proposed differentiation protocol. Furthermore, h UAs were efficiently repopulated by VSMCs. Differentiated VSMCs from WJ-MSCs could provide an alternative source of cells for vascular tissue engineering. 展开更多
关键词 Vascular smooth muscle CELLS Decellularized UMBILICAL ARTERIES Mesenchymal STROMAL CELLS MYOCD Cardiovascular disease Blood vessels
下载PDF
Antithrombotic therapy in TAVI
3
作者 Manolis Vavuranakis Konstantinos Kalogeras +10 位作者 Angelos Michail Kolokathis Dimitrios Vrachatis Nikolaos Magkoutis gerasimos siasos Euaggelos Oikonomou Maria Kariori Theodoros Papaioannou Maria Lavda Carmen Moldovan Ourania Katsarou Dimitrios Tousoulis 《Journal of Geriatric Cardiology》 SCIE CAS CSCD 2018年第1期66-75,共10页
Transcatheter 大动脉的阀门培植(TAVI ) 带重要 thromboembolic 和伴随物流血风险,不是仅仅在过程期间而且在 periprocedural 时期期间。有关在 TAVI 以后的最佳的 antithrombotic 治疗的许多问题仍然在争论下面。在现在的评论,我们... Transcatheter 大动脉的阀门培植(TAVI ) 带重要 thromboembolic 和伴随物流血风险,不是仅仅在过程期间而且在 periprocedural 时期期间。有关在 TAVI 以后的最佳的 antithrombotic 治疗的许多问题仍然在争论下面。在现在的评论,我们试图识别评估 antithrombotic 的所有相关研究在与在过程以后的临床的结果的关系的治疗学的策略。四使随机化控制试用(RCT ) 被识别他们与所有分析 post-TAVI antithrombotic 策略利用加 clopidogrel 终生的阿司匹林 3-6 月。,十七张注册表有关 antiplatelet 治疗被识别了,与关于基线特征的在他们之中的一个宽变化, clopidogrel 持续时间从 3-12 月正在。四非使随机化的试用被识别,比较在 TAVI 以后的单个对双的 antiplatelet 治疗,关于调查在为复杂并发症放血上的 thromboembolic 结果事件。最后,从单个 RCT 的有限数据和回顾的研究在过程和最佳的 antithrombotic 治疗期间关于抗凝剂处理存在什么时候伴随物 atrial 纤维性颤动。在结论,由于对待的人口的高风险和脆弱,在 TAVI 以后的 antithrombotic 治疗应该小心地被评估。减少的 ischaemic 和流血复杂并发症与在这个领域里要需要的进一步的研究在这些病人仍然是主要挑战。 展开更多
关键词 治疗学 阿司匹林 持续时间 有限数据 随机化 并发症 识别 大动脉
下载PDF
“Heart failure in COVID-19 patients: Critical care experience”: A letter to the editor
4
作者 Vasiliki Tsigkou gerasimos siasos +3 位作者 Evangelos Oikonomou Evanthia Bletsa Manolis Vavuranakis Dimitris Tousoulis 《World Journal of Virology》 2022年第4期216-220,共5页
Coronavirus disease 2019(COVID-19)is associated with poor cardiovascular outcomes in patients with heart failure(HF)of all categories of ejection fraction(EF),but mainly in patients with HF with reduced EF.Moreover,ca... Coronavirus disease 2019(COVID-19)is associated with poor cardiovascular outcomes in patients with heart failure(HF)of all categories of ejection fraction(EF),but mainly in patients with HF with reduced EF.Moreover,cardiac transplant patients exhibit worse cardiovascular prognosis,high mortality,and more admissions to the intensive care unit.In general,COVID-19 seems to deteriorate the clinical status of HF and favors the development of acute respiratory distress syndrome and multiorgan failure,especially in the presence of cardiovascular comorbidities such as diabetes mellitus,kidney dysfunction,and older age.COVID-19 may induce new-onset HF with complex mechanisms that involve myocardial injury.Indeed,myocardial injury comprises a large category of detrimental effects for the myocardium,such as myocardial infarction type 1 or type 2,Takotsubo cardiomyopathy,microvascular dysfunction and myocarditis,which are not easily distinguished by HF.The pathophysiologic mechanisms mainly involve direct myocardial damage by severe acute respiratory syndrome coronavirus 2,cytokine storm,hypercoagulation,inflammation,and endothelial dysfunction.The proper management of patients with COVID-19 involves careful patient evaluation and ongoing monitoring for complications such as HF. 展开更多
关键词 Heart failure COVID-19 PROGNOSIS Intensive care unit New onset heart failure Ejection fraction
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部